Page 4 - Sciad Communications News Today

NBP14 Targets Possible Primary Driver of Neurodegeneration Neuro-Bio Ltd, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate

Oxford, UK, 6th April 2022 / Sciad Newswire / Neuro-Bio Ltd, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease.Publishing their work in Alzheimer’s & D...

Cambridge, United Kingdom, 10th February 2022 / Sciad Newswire / Domainex Ltd., a leading integrated medicines research services partner, today announces it has opened a facility of over 7,000 sq ft at Unity Campus in Sawston – Cambridge’s newest science and technology park encompassing Iconix Park and The Works, an...

Saffron Walden, 26th January 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing a...

IRVING, Texas, Jan. 12, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) today announced that its Rousselot Health brand, the global leader of collagen-based solutions, has partnered

IRVING, Texas, Oct. 19, 2021 /PRNewswire/ -- Darling Ingredients Inc.'s (NYSE: DAR) health brand, Rousselot, the global leader of collagen-based solutions, today launches Quali-Pure, a range

Solentim expands European operations May 4, 2021 Bournemouth, UK, 5th May 2021 / Sciad Newswire / Solentim, the trusted global leader in workflows for antibody and cell-based therapies, today announced an expansion of its European operations. The company has established a new EU entity based in Ireland to facilitate frictionless business within the EU. Additionally, Solentim has opened a new warehousing and logistics hub in Germany, to better serve its customers with...

Darling Ingredients Inc. (NYSE: DAR) today announced that its Rousselot brand, the global leader of collagen-based solutions, expands its range of purified, pharmaceutical grade, modified gelatins with the launch of X-Pure® GelDAT – Gelatin Desaminotyrosine. Created in response to customer's demand to overcome the barriers encountered in clinical translation, this is the first, readily available biomaterial of its kind. X-Pure® GelDAT offers guaranteed purity and consistenc...

Future Planet Capital: Future Planet Invests in Vaccitechs Series B Financing Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into ...